Latest news with #PD1
USA Today
2 days ago
- Entertainment
- USA Today
Cowboys owner Jerry Jones reveals prior double hip replacements after cancer treatments
Jerry Jones revealed his cancer treatment required both hips to be replaced, sharing how the experience shaped his perspective on football, life, and his time with the Cowboys. While discussing America's Team: The Gambler and His Cowboys, the new Netflix documentary series chronicling the franchise's 1990s rise to prominence, Dallas owner Jerry Jones revealed new details about his past cancer battle. Jones' health became a topic after the series revealed his private fight with cancer starting in 2010, something he had not discussed publicly until now. The Hall of Fame owner said sharing his story was important because so many people face similar challenges, and he wanted fans to understand the perspective and gratitude he carried into each day with the Cowboys. Speaking to reporters Thursday, Jones shared that he underwent a clinical trial for a treatment called PD1 that 'really, really, really worked,' but at the cost of significant damage to his body. 'It ate my hips up,' Jones said. 'I had to have both hips replaced because it was rough on your bones. But other than that, I'm so proud to get to be sitting here with you guys and doing what we do.' Jones credited his time around the Cowboys and the NFL for helping him maintain a positive outlook during treatment. That same perspective carried into his experience watching the series, which he described as 'more emotional' than expected."It wasn't as pretty as I thought I remembered it. I made a lot of mistakes along the way," said Jones, "but... it did show moments of elation. That's football."He reflected that football is mostly about enduring challenges and working through tough moments, with only brief bursts of elation 'and there's not a whole lot in between,' according to the Cowboys Team: The Gambler and His Cowboys premieres August 19 on Netflix as an eight-part docuseries.
Medscape
3 days ago
- Health
- Medscape
Leukemia Relapse: PD-1 Inhibition Shows Mixed Results
TOPLINE: Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) relapse after hematopoietic cell transplantation (HCT). Mixed CD3 chimerism predicted response, but 37.5% developed severe graft-vs-host disease (GVHD). METHODOLOGY: A prospective phase 1B clinical trial enrolled 16 patients with AML (n = 12) and MDS (n = 4) who experienced relapse after HCT, with a median time to relapse of 5.5 months and median pretreatment bone marrow blast percentage of 21.5%. Participants received 200 mg pembrolizumab intravenously every 21 days for up to four cycles (induction), with responding patients eligible for maintenance therapy up to 1 year. Primary objectives included assessment of safety, overall response rate to pembrolizumab with or without subsequent chemotherapy, and rates of GVHD or clinically significant immune-mediated toxicity. Response evaluation occurred through bone marrow examination on day 35 (after cycle 2) and day 77 (after cycle 4), with complete remission defined as bone marrow blasts less than 5% and absence of circulating blasts. TAKEAWAY: The overall response rate was 31.3%, consisting of three complete remissions (18.8%) and two partial remissions (13.5%), with a median response duration of 610 days. Patients with mixed CD3 chimerism showed significantly higher response rates compared to those with full donor chimerism (50% vs 0%; P = .03). Severe (grades 3-4) GVHD developed in 37.5% of patients, with most cases resistant to corticosteroids and contributing to death in 25% of participants. The 1-year overall survival was 37.5% and event-free survival was 31.3%, with AML patients showing 1-year overall survival of 50.0%. IN PRACTICE: 'PD-1 inhibition led to durable remission in on -third of the patients experiencing early relapse after HCT, suggesting that this approach may augment the GVL [graft-vs-leukemia] response. Responses were exclusively observed in the setting of mixed CD3 donor chimerism. Immune toxicities (GVHD) were a barrier to successful treatment outcome,' the authors of the study wrote. 'The results of the study highlight the challenge of attempting to dissect the graft-vs-leukemia effect from immunologic toxicity in patients with HCT,' Roman M. Shapiro and Robert J. Soiffer, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, said in a press release. SOURCE: The study was led by John M. Magenau, Transplantation and Cell Therapy Program, University of Michigan Rogel Cancer Center in Ann Arbor, Michigan. It was published online on August 12 in Blood Advances. LIMITATIONS: According to the authors, the small sample size limited their ability to determine the extent to which pembrolizumab could separate graft-vs-leukemia effects from GVHD. The researchers note that, while some patients achieved response without GVHD, the limited cohort size may have confounded interpretation of significant variables, including response patterns in patients with high blast percentage, very early relapse, monosomal karyotype, or TP53 mutations. DISCLOSURES: Magenau declared receiving support through a National Institutes of Health career development award (K23AI123595) and a Rogel Cancer Center Scholarship. The study was supported by a research grant (54053) from the Investigator-Initiated Studies Program of Merck Sharp & Dohme LLC. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
New York Times
3 days ago
- Health
- New York Times
Cowboys' Jerry Jones reveals 2010 cancer diagnosis, overcame stage 4 melanoma
Netflix's eight-part documentary on the Dallas Cowboys drops next week and mostly examines the team's glory days in the 1990s. There is, however, a reference to a battle that Cowboys owner and general manager Jerry Jones won more recently. Jones made a passing reference in the documentary to undergoing cancer treatments 'about a dozen years ago.' Jones confirmed to the Dallas Morning News that he was diagnosed with stage 4 melanoma in June of 2010 and underwent treatment over the following decade. Advertisement Jones said he received 'fabulous' treatment at MD Anderson Cancer Center in Houston and overcame the cancer thanks to an experimental drug called PD-1, or Programmed Cell Death Protein 1, per the Dallas Morning News. A stage 4 cancer diagnosis means melanoma has spread to other places throughout the body, such as the brain, lungs, liver or gastrointestinal (GI) tract, and it may have spread to distant points in the skin, per the Melanoma Research Alliance. According to the National Library of Medicine, research showed that PD-1 'acted as a 'brake' role in immune function, and suggested that immune checkpoint inhibition may reactivate T cells and eliminate cancer cells more effectively.' T cells are part of the immune system and help protect the body from infection. Jones said he had two lung surgeries and two lymph node surgeries in the decade after his cancer diagnosis. He confirmed to the Dallas Morning News that he is tumor-free. Jones, 82, has held the title of Cowboys owner and general manager since he bought the franchise in 1989. After winning three Super Bowls in four years during the mid-90s with coach Jimmy Johnson, the team has struggled to find postseason success since. Dallas is in a 29-year championship drought and is the only NFC team to fail to reach a conference championship game over that span. The Cowboys have compiled a 319-261 record under Jones. Their last playoff appearance came in 2023, when they lost to the Green Bay Packers in the wild-card round. Spot the pattern. Connect the terms Find the hidden link between sports terms Play today's puzzle
Yahoo
4 days ago
- Health
- Yahoo
Jerry Jones reveals lengthy cancer battle
Yahoo Sports' Jason Fitz and Caroline Fenton react to the Dallas Cowboys owner's announcement that he battled stage four cancer for more than a decade. View more Video Transcript Welcome back to Yahoo Sports Daily. Breaking news. Cowboys owner Jerry Jones says he survived a stage 4 cancer battle that lasted more than a decade and included four surgeries. The story is out there right now on Yahoo, and Frank Schwab has written it. It should be noted that the initial diagnosis came in 2010. Over the next 10 years, he had four surgeries: two on his lungs, and two on his lymph nodes. He credited the experimental drug PD1 for his recovery. Quote, I would say by a fabulous treatment and great doctors, and a real miracle called PD1. Uh, this reminds us, Caroline, that there are things outside of just football in everybody's life, including Jerry Jones. Sometimes, uh, knowing that he was dealing with this from 2010 to 2020 is a reminder that we don't always have the full context of what's going on in people's lives while we talk about the sports that they're involved in. I think it's a reminder too that these are all humans. These are people, and unfortunately, cancer does not discriminate. It can hit anyone, whether it's, you know, just a regular person walking down the street or it's Jerry Jones. So thoughts and prayers to Jerry Jones and his family, and shout out to the miracle workers, truly all doctors across the globe that work to save lives, like Jerry Jones. He said that he is currently tumor-free. So at least good news there, but thoughts and prayers to his family. Absolutely. Close
Medscape
16-07-2025
- Health
- Medscape
Fact or Fiction: Bladder Cancer
Recent advances in immunotherapy, genomic profiling, and bladder-sparing techniques have begun to reshape diagnostic algorithms and treatment strategies across disease stages, from non-muscle-invasive to metastatic bladder cancer. Immunotherapies targeting PD-1 and PD-L1 have shown durable responses in certain subsets of patients, while next-generation sequencing helps guide decisions by identifying actionable mutations and molecular subtypes. Additionally, minimally invasive surgical techniques, improvements in intravesical therapies, and novel surveillance tools such as urinary biomarkers contribute to a more personalized, risk-adapted approach. As the field moves toward more integrated, multidisciplinary care, clinicians and care teams must stay abreast of these innovations to ensure optimal outcomes, improved quality of life, and equitable access to cutting-edge therapies. Checkpoint inhibitors such as atezolizumab, nivolumab, and pembrolizumab have been approved for patients with advanced or metastatic urothelial carcinoma, especially those ineligible for cisplatin-based chemotherapy or with disease progression after platinum therapy. These agents work by targeting PD-1 or PD-L1 pathways to enhance the immune system's ability to fight cancer. In recent years, nivolumab was approved for use in combination with cisplatin and gemcitabine as first-line treatment for unresectable or metastatic urothelial carcinoma, marking a major shift toward integrating immunotherapy earlier in treatment algorithms. Learn more about immunotherapy for bladder cancer. Cigarette smoking is the leading risk factor for bladder cancer, responsible for approximately 50% of all cases. Smokers are twice as likely to develop bladder cancer than nonsmokers. Smoking cessation significantly reduces risk over time, though former smokers remain at elevated risk compared to never-smokers. Occupational exposures, such as to benzidine and beta-naphthylamine, are also important, especially for long-term workers in underregulated environments. However, these exposures account for a smaller percentage of overall cases. Environmental exposures are increasingly being realized as a cause for bladder cancer. Pesticides and contaminated drinking water are concerns. Learn more about bladder cancer etiology. The majority of NMIBC cases are managed conservatively, starting with transurethral resection of bladder tumor (TURBT). At recurrence, however, intravesical therapy with instilled chemotherapy drugs, Bacillus Calmette-Guérin (BCG), and immediate radical cystectomy are options that should be discussed. Radical cystectomy is generally reserved for patients who are unresponsive to or who have high-grade T1 lesions with associated carcinoma in situ, lymphovascular invasion, or variant histology. Bladder preservation is a cornerstone of treatment for low- and intermediate-risk patients with NMIBC, aiming to maintain quality of life while achieving cancer control. Surveillance through periodic cystoscopy and urinary cytology is essential to detect recurrences, which are common. Learn more about treatment for NMIBC. Although several urinary biomarkers (eg, NMP22, UroVysion FISH, Cxbladder, bladder tumor antigen tests) are available, they have not replaced cystoscopy, which remains the cornerstone of surveillance. Cystoscopy provides direct visualization and allows for resection of visible tumors, whereas biomarkers have variable sensitivity and specificity with the potential for false positives. Urinary biomarkers are being incorporated as adjuncts to traditional surveillance, however, as they offer minimal discomfort and invasiveness for patients. Ongoing research is exploring novel biomarker panels and genomic assays to better personalize surveillance regimens and reduce the burden of routine cystoscopy without compromising oncologic safety. Learn more about long-term monitoring for bladder cancer. Neoadjuvant cisplatin-based chemotherapy, typically gemcitabine plus cisplatin (GC) or methotrexate-vinblastine-doxorubicin-cisplatin (MVAC), has been shown to improve overall survival, with some studies finding a 10% benefit in 5-year survival. As a result, neoadjuvant chemotherapy is considered a standard of care for eligible patients with muscle-invasive bladder cancer. For cisplatin-ineligible patients, ongoing trials are evaluating alternative treatment options in the neoadjuvant setting. Molecular subtyping, while there is not yet currently sufficient evidence to be the standard of care, may help to inform treatment decision-making and offer the potential for more targeted therapies. Learn more about neoadjuvant therapy for bladder cancer.
